The essential polyunsaturated fatty acids: Two families, one purpose

Last updated: May 21, 2026 Русский

For decades, dietary fat was often seen as a single, homogeneous entity – a dense source of calories to be limited for the sake of weight control and heart health. This simplistic view has given way to a far more nuanced and fascinating picture. Today, nutritional science recognizes that the type of fatty acid determines its biological fate, and among all dietary lipids, two specific molecules stand out as irreplaceable. These are the essential fatty acids (EFAs): linoleic acid (LA, 18:2ω‑6) and α‑linolenic acid (ALA, 18:3ω‑3).

The term “essential” carries a precise biochemical meaning: a nutrient that cannot be synthesized by the human body and therefore must be obtained from food. Unlike saturated or monounsaturated fatty acids, which can be built endogenously from simpler precursors, LA and ALA rely entirely on dietary supply (Retterstøl & Rosqvist, 2024). Their essentiality was established in the mid‑20th century through animal studies that demonstrated severe deficiency symptoms – poor growth, dermatitis, and reproductive failure – when these fatty acids were omitted from the diet. Subsequent research in humans receiving parenteral nutrition without EFAs confirmed that similar deficiency signs appear, underscoring their fundamental role in human biology (Jackson et al., 2024; Plourde & Cunnane, 2007).

Why are these two molecules so special? The answer lies in their unique chemical structure. Both are 18‑carbon polyunsaturated fatty acids (PUFAs) with multiple cis double bonds. LA belongs to the omega‑6 (ω‑6) family, with its first double bond located on the sixth carbon from the methyl end, while ALA belongs to the omega‑3 (ω‑3) family, with the first double bond on the third carbon. Animals, including humans, possess the enzymatic machinery to further desaturate and elongate these 18‑carbon precursors into longer, more highly unsaturated fatty acids – notably arachidonic acid (AA, 20:4ω‑6) from LA, and eicosapentaenoic acid (EPA, 20:5ω‑3) and docosahexaenoic acid (DHA, 22:6ω‑3) from ALA (Saini & Keum, 2018). These long‑chain products serve critical structural and signaling roles in cell membranes, the nervous system, and the immune response.

However, the efficiency of this conversion pathway in humans is remarkably low, especially for the production of DHA. Stable isotope studies indicate that only about 0.5‑5% of dietary ALA is converted to EPA, and often less than 1% to DHA (Plourde & Cunnane, 2007; Baker et al., 2016). Most of the ingested ALA is instead directed toward β‑oxidation – used as fuel – or stored in adipose tissue. This metabolic bottleneck has profound implications: it means that the long‑chain ω‑3 PUFAs EPA and DHA, which are concentrated in seafood and algae, are functionally irreplaceable for certain physiological processes, despite the theoretical precursor role of ALA.

The interplay between the ω‑6 and ω‑3 families is equally important. Both share the same set of desaturase and elongase enzymes, creating a competitive relationship. A high dietary intake of LA, characteristic of many Western diets rich in vegetable oils, can suppress the already limited conversion of ALA to EPA and DHA (Innes & Calder, 2018). This competition has fueled decades of research into the optimal balance of ω‑6 and ω‑3 fatty acids – a topic often reduced to simplistic ratios but, as will be discussed, far more complex in reality.

This article provides an educational overview of essential fatty acids, focusing on their biochemistry, metabolism, and physiological functions. It does not offer clinical advice or treatment recommendations. Instead, it aims to clarify the fundamental concepts that any student of nutrition should understand: what EFAs are, why they are indispensable, how the body handles them, and why the distinction between plant‑derived precursors and marine‑derived long‑chain PUFAs matters for human health. We will explore the roles of LA and ALA as structural components, the route of their conversion, the functions of their long‑chain products (AA, EPA, and DHA), and the emerging understanding of lipid mediators that orchestrate cellular responses. By the end, the reader will appreciate why these two families of fatty acids are not merely “good fats” but essential players in the molecular architecture of life.

1. The main actors: Alpha-linolenic acid (ALA) and linoleic acid (LA)

Before we can appreciate the complex metabolism and far‑reaching functions of the two essential fatty acid families, we must first introduce the two principal molecules that start everything: linoleic acid (LA) for the ω‑6 series, and α‑linolenic acid (ALA) for the ω‑3 series. These 18‑carbon polyunsaturated fatty acids (PUFAs) are the only true dietary “essentials” in the world of lipids. All other PUFAs – including arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) – can theoretically be made from LA and ALA, although, as we shall see, the conversion efficiency in humans is unexpectedly low (Plourde & Cunnane, 2007; Baker et al., 2016).

1.1 Linoleic acid (LA, 18:2ω‑6): the abundant ω‑6

Linoleic acid is an 18‑carbon chain with two cis double bonds. Its systematic name is all‑cis‑9,12‑octadecadienoic acid. The first double bond, counting from the methyl (omega) end, is located at carbon number 6 – this defines it as an ω‑6 fatty acid. In the shorthand notation used by lipid biochemists, LA is written as 18:2ω‑6 or 18:2n‑6, where “18” is the number of carbon atoms, “2” is the number of double bonds, and “ω‑6” indicates the position of the first double bond (Saini & Keum, 2018).

In nature, LA is remarkably abundant. It is the predominant PUFA in most vegetable oils, including sunflower, safflower, corn, soybean, and grapeseed oils. Nuts (especially walnuts), seeds (such as pumpkin and sesame seeds), and products made from these oils (margarines, salad dressings) are also rich sources. Because of the widespread use of these oils in processed foods and cooking, LA intakes in Western‑style diets are typically high – often contributing 5‑7% of total daily energy (Jackson et al., 2024; Retterstøl & Rosqvist, 2024).

Why is LA essential? At the cellular level, LA serves three broad functions:

  • Membrane architecture. Along with saturated and monounsaturated fatty acids, LA is incorporated into membrane phospholipids. Its cis double bonds introduce “kinks” in the hydrocarbon chain, which increase membrane fluidity and flexibility – properties that are crucial for membrane protein function, vesicle trafficking, and cell signaling (Hashimoto et al., 2017).
  • Precursor function. LA is the starting material for the synthesis of other ω‑6 PUFAs, notably arachidonic acid (AA). This pathway involves a sequence of desaturation and elongation steps, as detailed in Part 2.
  • Skin barrier integrity. One unique role of LA is its presence in epidermal ceramides. These lipid molecules form the water‑impermeable barrier of the stratum corneum. Without adequate LA, the skin barrier becomes defective, leading to excessive transepidermal water loss and the scaly dermatitis characteristic of essential fatty acid deficiency (Innes & Calder, 2018; Jackson et al., 2024).

A clinical deficiency of LA is very rare in free‑living, healthy individuals on mixed diets. It has been described primarily in patients receiving long‑term fat‑free parenteral nutrition or in infants fed formulas severely deficient in ω‑6 PUFAs. Symptoms include dry, scaly skin, growth retardation, and impaired wound healing (Retterstøl & Rosqvist, 2024). The estimated minimum requirement to prevent overt deficiency is surprisingly low – probably around 1‑2% of energy as LA – but most national guidelines recommend higher intakes (5‑10% of energy) to achieve optimal health outcomes (Jackson et al., 2024).

1.2 Alpha‑linolenic acid (ALA, 18:3ω‑3): the plant‑derived ω‑3

Alpha‑linolenic acid is also an 18‑carbon fatty acid, but with three cis double bonds. Its systematic name is all‑cis‑9,12,15‑octadecatrienoic acid. The first double bond is located at carbon 3 from the methyl end, placing it in the ω‑3 family. Its shorthand notation is 18:3ω‑3 or 18:3n‑3 (Saini & Keum, 2018).

ALA is far less abundant in the food supply than LA. The richest plant sources are flaxseed (linseed) and flaxseed oil (where ALA may exceed 50% of total fatty acids), chia seeds, walnuts, hemp seeds, and certain vegetable oils such as canola (rapeseed) oil and soybean oil. Smaller amounts are found in green leafy vegetables, where ALA is present in chloroplast membranes. Unlike LA, ALA is not typically a major component of most processed foods, although food fortification with flaxseed or canola oil has increased its presence in some products (Baker et al., 2016).

The physiological roles of ALA can be divided into its own intrinsic actions and its role as a precursor. On its own, ALA is known to:

  • Serve as a membrane fatty acid. Like LA, ALA is incorporated into phospholipids, although its levels in most tissues are usually low compared to LA and long‑chain PUFAs.
  • Influence lipid metabolism. In controlled dietary interventions, replacing some saturated fat with ALA has been shown to lower total and LDL cholesterol (Retterstøl & Rosqvist, 2024). This effect is similar to that of LA and is attributed to the general properties of unsaturated fats on hepatic cholesterol metabolism.
  • Act as a precursor for longer ω‑3 PUFAs. As we will discuss in Part 2, ALA can be converted – albeit inefficiently – to eicosapentaenoic acid (EPA) and to a much smaller extent to docosahexaenoic acid (DHA).

ALA deficiency is even rarer than LA deficiency in the general population. It has been documented in some patients on long‑term fat‑free parenteral nutrition, with symptoms including peripheral neuropathy and visual disturbances – effects that reflect the critical need for DHA in neural tissues (Plourde & Cunnane, 2007). The minimum intake required to prevent deficiency is not precisely known, but international bodies recommend at least 0.5‑1% of energy as ALA, with a higher target (around 1% of energy) for pregnant and lactating women (Retterstøl & Rosqvist, 2024).

1.3 Why both are essential – and why they are not interchangeable

Because LA and ALA are both 18‑carbon PUFAs with similar physical properties, one might wonder whether one could substitute for the other. The answer is a clear no. Each family gives rise to its own distinct set of longer‑chain metabolites, and these metabolites have separate, non‑overlapping functions. For example, DHA derived from ALA is essential for the structure and function of the retina and brain, while AA derived from LA is a major component of membrane phospholipids in almost all cells and a precursor for signaling molecules involved in inflammation and platelet aggregation (Hashimoto et al., 2017; Innes & Calder, 2018). An LA‑deficient diet cannot be rescued by ALA, and vice versa.

Furthermore, the two families compete for the same desaturase and elongase enzymes. This competition means that the ratio of LA to ALA in the diet can influence the rate of conversion of ALA to EPA and DHA – a crucial point that will be explored in the next section.

In summary, linoleic acid and α‑linolenic acid are the two nutritionally essential fatty acids. They are abundant in plant‑based foods, but their distribution is highly unequal: LA is ubiquitous in modern diets, while ALA is concentrated in a few specific seeds and oils. Their essentiality arises from the body’s inability to create the initial ω‑6 or ω‑3 double bond, and from the fact that they serve as irreplaceable precursors for a host of longer‑chain PUFAs that regulate membrane fluidity, cell signaling, and tissue function. Understanding where they come from and what they do is the first step toward making sense of the more complex world of long‑chain PUFAs and their health implications.

2. The long chain: The path from short to long PUFA

As established in Part 1, linoleic acid (LA) and α‑linolenic acid (ALA) are the only nutritionally essential polyunsaturated fatty acids. Yet, paradoxically, the most abundant PUFA in the membranes of most human cells is not LA or ALA, but arachidonic acid (AA, 20:4ω‑6) – a 20‑carbon, four‑double‑bond ω‑6 fatty acid derived from LA. Likewise, the mammalian brain and retina accumulate large amounts of docosahexaenoic acid (DHA, 22:6ω‑3), a 22‑carbon, six‑double‑bond ω‑3 fatty acid ultimately derived from ALA (Hashimoto et al., 2017). This discrepancy between dietary intake and tissue composition is explained by the existence of a metabolic pathway that converts the 18‑carbon precursors into their longer, more unsaturated counterparts. This pathway – the desaturation‑elongation pathway – is the subject of this part.

2.1 Why the body needs longer chains

Membrane phospholipids are not just passive barriers; their fatty acid composition profoundly influences biophysical properties. Saturated fatty acids pack tightly, creating rigid, ordered domains; unsaturated fatty acids introduce kinks that increase fluidity and create spaces for membrane proteins to move and function. As chain length increases and more double bonds are added, the fatty acid becomes increasingly flexible and resistant to packing. DHA, with its six cis double bonds in a 22‑carbon chain, is the most extreme example: it adopts a highly bent, spring‑like conformation that imparts exceptional fluidity to membranes in which it is incorporated. This property is essential for the rapid conformational changes of rhodopsin in the retina and for the fusion and fission events involved in neurotransmitter release at synapses (Hashimoto et al., 2017). AA, though less unsaturated than DHA, also confers specific properties and serves as a reservoir for signalling molecules. Thus, the conversion of dietary LA and ALA into long‑chain PUFA is not a biochemical luxury – it is a necessity for normal cell function.

2.2 The desaturation‑elongation pathway: a shared route

Metabolic pathway of LA and ALA conversion to AA, EPA and DHA

Pathway of conversion of essential fatty acids to their more unsaturated and longer chain derivatives.

The ω‑6 and ω‑3 families share the same desaturase and elongase enzymes. Δ6‑desaturation is the rate‑limiting step. EPA can be further converted to DHA via the Sprecher pathway (not shown in detail). Djuricic & Calder (2021), Figure 3. CC BY 4.0

The conversion of LA to AA and of ALA to EPA and DHA follows the same sequence of enzymatic reactions, occurring primarily in the endoplasmic reticulum of liver cells, but also to a lesser extent in other tissues such as brain and retina. The pathway involves alternating desaturation (insertion of a new double bond) and elongation (addition of two carbon atoms) (Saini & Keum, 2018).

For the ω‑6 series, starting from LA (18:2ω‑6):

  1. Δ6‑desaturation (catalysed by Δ6‑desaturase, encoded by the FADS2 gene) introduces a double bond at position 6 from the carboxyl end, producing γ‑linolenic acid (GLA, 18:3ω‑6).
  2. Elongation (via elongase 5, encoded by ELOVL5) adds two carbons, forming dihomo‑γ‑linolenic acid (DGLA, 20:3ω‑6).
  3. Δ5‑desaturation (catalysed by Δ5‑desaturase, encoded by FADS1) inserts another double bond at position 5, yielding arachidonic acid (AA, 20:4ω‑6).

For the ω‑3 series, starting from ALA (18:3ω‑3):

  1. Δ6‑desaturation converts ALA to stearidonic acid (SDA, 18:4ω‑3).
  2. Elongation produces eicosatetraenoic acid (ETA, 20:4ω‑3).
  3. Δ5‑desaturation yields eicosapentaenoic acid (EPA, 20:5ω‑3).

The synthesis of DHA from EPA is more complex and involves an additional two elongation steps, a second Δ6‑desaturation, and a final chain‑shortening reaction in peroxisomes – a pathway often referred to as the “Sprecher pathway” (Baker et al., 2016; Plourde & Cunnane, 2007).

An important parallel pathway exists for ω‑6 PUFA: DGLA can be further elongated to adrenic acid (22:4ω‑6) and then through a similar sequence to ω‑6 docosapentaenoic acid (22:5ω‑6). These longer ω‑6 PUFA are present in smaller amounts and their functions are less well understood.

2.3 Competition: the ω‑6 and ω‑3 families share enzymes

A critical feature of this metabolic pathway is that the same enzymes – particularly Δ6‑desaturase and Δ5‑desaturase – accept both ω‑6 and ω‑3 substrates. However, the enzymes show a preference for ω‑3 over ω‑6 fatty acids. In isolated enzyme assays, the Km (a measure of affinity) of Δ6‑desaturase for ALA is approximately 29‑33 µM, whereas for LA it is 43‑92 µM, indicating that ALA is a somewhat preferred substrate (Baker et al., 2016). Nevertheless, in the typical human diet, LA intake is often five to fifteen times higher than ALA intake. This numerical dominance of LA means that, despite the enzyme’s preference for ALA, the absolute amount of LA undergoing metabolism may be greater, and high LA levels can competitively inhibit the conversion of ALA to EPA and DHA (Innes & Calder, 2018; Jackson et al., 2024).

This competitive relationship has important nutritional implications. It suggests that simply increasing ALA intake may not effectively raise EPA and DHA status if LA intake remains very high. Conversely, lowering LA intake while maintaining ALA intake could enhance the conversion of ALA to its long‑chain products. Experimental studies in humans have confirmed this principle (Baker et al., 2016).

2.4 The conversion bottleneck: very low efficiency in humans

Despite the presence of a complete set of desaturase and elongase enzymes, the actual in vivo conversion of ALA to EPA, and especially to DHA, is remarkably inefficient in healthy adults. This conclusion is supported by two complementary lines of evidence: stable isotope tracer studies and long‑term dietary supplementation trials.

Stable isotope studies. When volunteers ingest a small amount of ALA labelled with deuterium (²H) or carbon‑13 (13C), researchers can track the appearance of the label in blood lipids. Using this technique, most studies report that only about 0.2‑8% of the labelled ALA appears as EPA, and conversion to DHA is typically less than 1% – often as low as 0.01‑0.05% (Plourde & Cunnane, 2007; Baker et al., 2016). In men, conversion to DHA is frequently undetectable, while young women show somewhat higher conversion rates (up to 9% for DHA in some reports), possibly reflecting oestrogen effects (Baker et al., 2016).

Supplementation studies. When healthy adults consume ALA‑rich oils (e.g., flaxseed oil) for several weeks, blood levels of EPA reliably increase, but DHA levels usually do not change or may even decrease slightly (Baker et al., 2016). This pattern – a clear rise in EPA but no change or a fall in DHA – has been observed repeatedly. For example, a meta‑analysis of intervention trials shows a dose‑dependent increase in plasma phospholipid EPA with increasing ALA intake, but no significant relationship with DHA (Baker et al., 2016).

These findings indicate that the bottleneck in the pathway lies beyond EPA. The conversion of EPA to DHA is the truly rate‑limiting step in humans. The reasons are not fully understood but may involve the complex peroxisomal β‑oxidation step required to shorten a 24‑carbon intermediate to DHA.

What happens to the ALA that is not converted to long‑chain PUFA? The majority is rapidly β‑oxidised to acetyl‑CoA, which enters the tricarboxylic acid cycle to produce energy, or is used for de novo synthesis of saturated and monounsaturated fatty acids (carbon recycling). Approximately 15‑35% of a single dose of ALA is oxidised within hours, and over seven days, up to 70% of ALA carbon may be recovered as CO2 (Plourde & Cunnane, 2007). Thus, ALA is primarily a fuel molecule, and only a tiny fraction becomes DHA.

2.5 Factors that influence conversion efficiency

While the overall capacity of the pathway is low, there is considerable inter‑individual variation. Several factors modulate the conversion of ALA to EPA and DHA:

  • Sex. As noted, young women consistently show higher conversion to DHA than men. This difference is largely attributed to oestrogen, which upregulates the expression of Δ6‑desaturase and Δ5‑desaturase. Oral contraceptive use further increases DHA synthesis, while androgen administration decreases it (Baker et al., 2016).
  • Genetic polymorphisms. Single nucleotide polymorphisms (SNPs) in the FADS1 and FADS2 genes (encoding Δ5‑ and Δ6‑desaturase) have a major impact on PUFA metabolism. Carriers of certain minor alleles have lower desaturase activity and consequently lower plasma levels of AA and DHA, even when ALA intake is adequate. These genetic variants are common and can explain a significant portion of the variability in long‑chain PUFA status among individuals (Baker et al., 2016; Retterstøl & Rosqvist, 2024).
  • Dietary background. As mentioned, high LA intake inhibits ALA conversion. Conversely, a low LA:ALA ratio favours the production of EPA and DHA. The absolute amounts of both fatty acids matter more than their ratio alone, but reducing LA intake enhances the efficiency of ALA conversion (Baker et al., 2016; Jackson et al., 2024). The presence of pre‑formed EPA and DHA in the diet also downregulates the pathway via feedback inhibition.
  • Nutritional status. Desaturase enzymes require several micronutrients as cofactors, including iron, zinc, magnesium, and vitamins B2, B6, and B3 (niacin). Deficiencies in these nutrients can impair desaturase activity, further reducing conversion efficiency. Adequate protein intake is also necessary for enzyme synthesis (Plourde & Cunnane, 2007).
  • Age and health status. Newborns and infants appear to have a somewhat higher capacity to synthesise DHA from ALA than adults, presumably because of the high demand for DHA during brain development. In the elderly, conversion efficiency may decline, although data are limited. Certain disease states (e.g., liver disease, diabetes) can also affect desaturase activity (Baker et al., 2016).

2.6 Summary: a pathway of limited capacity

The desaturation‑elongation pathway is a remarkable metabolic system that allows humans to produce essential long‑chain PUFAs from simpler plant‑derived precursors. However, its capacity is severely limited. In healthy adults, only a small percentage of ALA is converted to EPA, and an even smaller fraction (often less than 1%) becomes DHA. This low efficiency has three important consequences:

  1. For most people, tissue levels of EPA and DHA are strongly determined by direct dietary intake of these long‑chain PUFAs from fish, seafood, and other marine sources, rather than by endogenous synthesis from ALA.
  2. Strategies that rely solely on increasing ALA intake (e.g., consuming more flaxseed oil) will raise EPA levels modestly but will not meaningfully increase DHA status in most individuals.
  3. The competition between ω‑6 and ω‑3 families means that a high LA intake (typical of Western diets) may further impair the already limited synthesis of EPA and DHA from ALA.

Thus, while ALA is an essential nutrient, its role as a precursor for DHA is constrained by biology. In the next part, we will examine the functions of the long‑chain products themselves – arachidonic acid, EPA, and DHA – and why they are so central to cellular physiology.

3. The long‑chain products: Arachidonic acid (AA), EPA and DHA

The conversion of linoleic acid (LA) and α‑linolenic acid (ALA) into their respective long‑chain metabolites is an essential metabolic pathway, but as we saw in Part 2, its capacity in humans is severely limited. The true significance of this pathway lies not in its efficiency, but in the biological potency of its end products. Three long‑chain polyunsaturated fatty acids stand out as the principal functional molecules derived from the essential precursors: arachidonic acid (AA, 20:4ω‑6) from the ω‑6 family, and eicosapentaenoic acid (EPA, 20:5ω‑3) and docosahexaenoic acid (DHA, 22:6ω‑3) from the ω‑3 family. These molecules are not merely metabolic intermediates; they are central players in membrane architecture, cellular signalling, and the regulation of physiological responses.

3.1 Arachidonic acid (AA): the dominant ω‑6 in cell membranes

Arachidonic acid is a 20‑carbon ω‑6 PUFA with four cis double bonds (at positions 5, 8, 11, and 14). In the shorthand notation, it is written as 20:4ω‑6. AA is the most abundant long‑chain PUFA in the membrane phospholipids of virtually all mammalian cells. In human peripheral blood mononuclear cells, for example, AA typically comprises 15‑20% of total fatty acids – far exceeding the contributions of LA (around 10%) or any individual ω‑3 PUFA (Innes & Calder, 2018).

Dietary sources of pre‑formed AA include meat (especially red meat and organ meats such as liver), poultry, eggs, and fish. The daily intake in Western diets is estimated to be between 100 and 350 mg, which is less than 0.1% of total energy. In addition to dietary intake, AA can be synthesised endogenously from LA, although the conversion is limited and, interestingly, increasing LA intake does not significantly increase tissue AA levels in people consuming typical Western diets. This suggests that the pathway is already saturated and that dietary LA is not a major determinant of AA status under normal conditions (Innes & Calder, 2018; Jackson et al., 2024).

The primary functions of AA are structural and signalling‑related:

  • Membrane structure and fluidity. As a highly unsaturated fatty acid, AA contributes to the fluidity, flexibility, and proper functioning of membrane proteins. It is particularly enriched in phospholipids at the sn‑2 position of the glycerol backbone, from which it can be readily released by phospholipase A₂ enzymes upon cellular activation.
  • Reservoir for eicosanoids. AA is the principal precursor for a large family of signalling molecules collectively known as eicosanoids. These include prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs). Through the action of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, AA is converted into more than 50 distinct mediators (Innes & Calder, 2018; Djuricic & Calder, 2021).
  • Precursor for endocannabinoids. AA is also a component of endocannabinoids such as anandamide (arachidonoyl ethanolamide) and 2‑arachidonoylglycerol (2‑AG), which act on cannabinoid receptors to modulate neurotransmission, pain perception, and appetite (Djuricic & Calder, 2021).

A common misconception is that AA is inherently “pro‑inflammatory” and therefore undesirable. While it is true that many AA‑derived eicosanoids (e.g., PGE₂, LTB₄) are potent mediators of inflammation, this is only one side of the story. First, these mediators are essential components of normal host defence and tissue repair – they are not intrinsically harmful. Second, AA also gives rise to lipoxins (e.g., LXA₄), which are specialised pro‑resolving mediators that actively terminate inflammation and promote healing (Innes & Calder, 2018). Thus, AA is best understood as a versatile precursor whose metabolic products can have opposing effects depending on the context and the enzymes involved.

3.2 Eicosapentaenoic acid (EPA): the signalling ω‑3

Eicosapentaenoic acid is a 20‑carbon ω‑3 PUFA with five cis double bonds (positions 5, 8, 11, 14, 17). Its shorthand is 20:5ω‑3. EPA is present in lower amounts in human tissues than AA, typically accounting for less than 1‑2% of total fatty acids in blood cells in individuals who do not regularly consume oily fish (Djuricic & Calder, 2021).

The primary dietary sources of EPA are marine: fatty fish (such as salmon, mackerel, herring, and sardines), other seafood (oysters, mussels), and algae. Small amounts are also present in meat and eggs from animals fed ω‑3‑enriched diets, but these are not major contributors in typical Western diets. Like AA, EPA can also be synthesised endogenously from ALA, but as discussed in Part 2, the conversion is inefficient – typically less than 5% of ALA appears as EPA in blood lipids (Baker et al., 2016).

The functions of EPA overlap with those of AA in some respects but are distinct in others:

  • Competitive inhibition of AA metabolism. EPA is also a substrate for COX and LOX enzymes. Because it competes with AA for access to these enzymes, a higher EPA to AA ratio shifts eicosanoid production away from AA‑derived (series‑2 and series‑4) mediators towards EPA‑derived (series‑3 and series‑5) mediators. These EPA‑derived eicosanoids are generally less potent in their pro‑inflammatory actions or may even have opposing, anti‑inflammatory effects (Djuricic & Calder, 2021).
  • Precursor for resolvins of the E series. EPA is the direct precursor for a family of specialised pro‑resolving mediators (SPMs) called E‑series resolvins (RvE1, RvE2, RvE3). These molecules actively promote the resolution of inflammation by limiting neutrophil infiltration, enhancing macrophage clearance of apoptotic cells, and stimulating tissue repair (Ishihara et al., 2019; Djuricic & Calder, 2021).
  • Membrane incorporation. EPA can replace AA in membrane phospholipids, thereby altering membrane properties and reducing the pool of AA available for eicosanoid synthesis. Unlike DHA, EPA is not highly enriched in the brain or retina, but it does accumulate in other tissues, including the heart, liver, and immune cells.

In summary, EPA acts as a metabolic modulator. It does not serve a unique structural role comparable to DHA, but its ability to compete with AA and to generate anti‑inflammatory and pro‑resolving mediators makes it a key regulator of inflammatory processes.

3.3 Docosahexaenoic acid (DHA): the structural ω‑3

Docosahexaenoic acid is a 22‑carbon ω‑3 PUFA with six cis double bonds (positions 4, 7, 10, 13, 16, 19). Its shorthand is 22:6ω‑3. DHA is the longest and most highly unsaturated of the common dietary PUFA. It possesses a unique conformation: the six double bonds force the molecule into a highly bent, spring‑like shape that confers exceptional flexibility and fluidity to the membranes in which it resides (Hashimoto et al., 2017).

DHA is concentrated in a few specific tissues. In the brain, it accounts for 10‑20% of total fatty acids in grey matter and up to 40% of the PUFA in synaptic membranes. In the retina, DHA is even more abundant, comprising approximately 50‑60% of the fatty acids in the outer segment disk membranes of photoreceptor cells. The testes also contain relatively high levels of DHA, suggesting a role in sperm maturation and motility (Hashimoto et al., 2017).

Dietary sources of DHA are almost exclusively marine: fatty fish, fish oils, and algal oils. Unlike EPA, DHA is present only in trace amounts in terrestrial animals and plants. Endogenous synthesis from ALA is extremely limited in adults – often undetectable – and even from EPA, the conversion is minimal (Plourde & Cunnane, 2007; Baker et al., 2016). This means that for most adults, DHA status is directly dependent on dietary intake of pre‑formed DHA.

The functions of DHA are primarily structural, but with profound physiological consequences:

  • Membrane fluidity and protein function. The unique conformation of DHA increases the fluidity of membrane bilayers, reduces the packing of lipid acyl chains, and creates a dynamic environment for membrane proteins. In photoreceptor cells, DHA is essential for the rapid conformational changes of rhodopsin that underlie visual transduction. In neurons, DHA modulates the properties of ion channels, neurotransmitter receptors, and synaptic vesicle fusion (Hashimoto et al., 2017).
  • Lipid raft modulation. DHA is excluded from ordered lipid rafts (cholesterol‑ and sphingolipid‑rich microdomains) and instead promotes the formation of more fluid, disordered domains. By altering raft composition and distribution, DHA influences the localisation and signalling of proteins associated with rafts, including many immune receptors and growth factor receptors (Hashimoto et al., 2017).
  • Precursor for D‑series resolvins, protectins, and maresins. DHA is the parent molecule for several families of SPMs: D‑series resolvins (RvD1‑RvD6), protectins (including PD1 and PDX), and maresins (MaR1, MaR2). These mediators are generated by the action of 15‑lipoxygenase and other enzymes and are among the most potent known endogenous molecules for resolving inflammation and promoting tissue regeneration (Ishihara et al., 2019; Djuricic & Calder, 2021). Recently, additional conjugated forms – such as maresin conjugates in tissue regeneration (MCTRs) and protectin conjugates in tissue regeneration (PCTRs) – have been identified, expanding the repertoire of DHA‑derived bioactive mediators.
  • Neuroprotection and brain development. DHA is essential for neurite outgrowth, synaptogenesis, and the survival of developing neurons. It also promotes adult neurogenesis in the hippocampus, a region critical for learning and memory. DHA deficiency during development leads to permanent deficits in visual acuity and cognitive function, which is why DHA is now routinely added to infant formulas worldwide (Hashimoto et al., 2017).

3.4 How AA, EPA and DHA interact in cells

SPM synthesis from EPA and DHA

Overview of the conversion of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to lipid mediators, including specialized pro‑resolving mediators (resolvins, protectins, maresins).

COX – cyclooxygenase; LOX – lipoxygenase. E‑series resolvins are derived from EPA; D‑series resolvins, protectins and maresins are derived from DHA. Source: Djuricic & Calder (2021), Figure 5. CC BY 4.0

In any given cell type, the relative proportions of AA, EPA and DHA in membrane phospholipids are determined by a combination of dietary intake, endogenous synthesis, and remodelling cycles (the Lands cycle). These three long‑chain PUFA do not act in isolation; they compete for incorporation into membrane phospholipids, for release by phospholipases, and for metabolism by downstream enzymes.

A cell with a high AA to EPA ratio will predominantly produce AA‑derived eicosanoids (series‑2 prostaglandins, series‑4 leukotrienes). A cell in which EPA has displaced some AA will generate EPA‑derived eicosanoids (series‑3 prostaglandins, series‑5 leukotrienes) alongside AA metabolites. This shift is generally associated with a less pro‑inflammatory profile. DHA, while also competing with AA, is less efficiently released by most phospholipases and therefore acts more as a structural modifier than a direct substrate for rapid signalling. However, DHA is a major source of SPMs, which act later in the inflammatory response to promote resolution (Innes & Calder, 2018; Ishihara et al., 2019).

Thus, the three long‑chain PUFA can be thought of as a functional triad. AA provides rapid, potent pro‑inflammatory signals that are essential for host defence. EPA acts as a modulator, dampening AA‑derived signals and contributing to early resolution. DHA is the principal structural ω‑3 in excitable membranes and the primary source of the most potent pro‑resolving mediators. An optimal balance among them – rather than elimination of any one – appears to be the goal of normal physiology.

3.5 The special case of docosapentaenoic acid (DPA)

Docosapentaenoic acid exists in two isomers: ω‑3 DPA (22:5ω‑3) and ω‑6 DPA (22:5ω‑6). ω‑3 DPA is an intermediate in the conversion of EPA to DHA and can be detected in human blood and tissues at levels that often exceed those of EPA. For many years, DPA was regarded merely as a metabolic stepping‑stone, but recent evidence suggests that it has its own biological activities. ω‑3 DPA can be converted to D‑series resolvins, protectins, and maresins, and may also serve as a reservoir for EPA synthesis via retroconversion. However, much less is known about DPA compared to EPA and DHA, and it remains an active area of research (Ishihara et al., 2019; Djuricic & Calder, 2021).

3.6 Summary: from precursors to functional molecules

Linoleic acid and α‑linolenic acid are essential because they provide the carbon skeletons for the synthesis of AA, EPA and DHA. However, the conversion efficiency is low, and for DHA, it is negligible in most adults. AA is the dominant long‑chain PUFA in most cell membranes and serves as a precursor for a wide range of eicosanoids, including both pro‑inflammatory and pro‑resolving mediators. EPA is a modulator that competes with AA and gives rise to less inflammatory eicosanoids and E‑series resolvins. DHA is a unique structural fatty acid essential for the function of the brain, retina, and other excitable tissues, and is the parent molecule for the most potent pro‑resolving mediators (D‑series resolvins, protectins, and maresins). Understanding these distinct roles is essential for interpreting why direct dietary sources of EPA and DHA (from fish, seafood, and algae) have different physiological effects than plant‑based ALA alone, even though they share a common metabolic ancestry.

4. Modern perspectives on balance and intake

The preceding parts have established the biochemical foundation: linoleic acid (LA) and α‑linolenic acid (ALA) are the two essential fatty acids, their conversion to long‑chain polyunsaturated fatty acids (PUFAs) is limited in humans, and the products – arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) – have distinct, non‑interchangeable roles in membrane structure and cell signalling. This knowledge naturally leads to practical questions: How much of each fatty acid should we consume? What is the optimal balance between ω‑6 and ω‑3 families? Can plant‑based ALA adequately replace marine EPA and DHA? This part addresses these questions from a nutritional science perspective, focusing on current understanding rather than clinical prescriptions.

4.1 The ratio debate: from simple dichotomy to nuanced reality

For several decades, a simple message dominated public discussions of PUFAs: ω‑3 fatty acids are “good” (anti‑inflammatory, cardioprotective), while ω‑6 fatty acids are “bad” (pro‑inflammatory, potentially harmful). This dichotomy was often expressed as a target ratio of ω‑6 to ω‑3 intake, typically 4:1 or lower, contrasting with the estimated 10:1 to 20:1 ratio in modern Western diets (Jackson et al., 2024; Retterstøl & Rosqvist, 2024). While intuitively appealing, this ratio concept has several limitations that modern research has brought into focus.

First, not all ω‑6 fatty acids are equivalent. LA (the major dietary ω‑6) and AA (the longer‑chain product) have different biological effects. As discussed in Part 3, AA is indeed a precursor for pro‑inflammatory eicosanoids, but it also gives rise to lipoxins that resolve inflammation. Moreover, increasing LA intake does not substantially raise tissue AA levels in people consuming typical Western diets (Innes & Calder, 2018). The presumed direct link from dietary LA to pro‑inflammatory AA metabolites is therefore much weaker than once thought.

Second, not all ω‑3 fatty acids are equivalent. ALA (the plant‑derived ω‑3) has very different biological activities compared to EPA and DHA. As shown in Part 2, conversion of ALA to EPA is limited and conversion to DHA is negligible in most adults. Thus, a dietary ratio that lumps ALA together with EPA and DHA obscures more than it clarifies.

Third, the ratio ignores absolute intakes. A ratio of 5:1 could be achieved by consuming 5 g of LA and 1 g of ALA, or by consuming 25 g of LA and 5 g of ALA. The absolute amounts matter because they determine the total flux through the shared desaturase‑elongation pathway and the competitive inhibition between the two families. Goyens and colleagues demonstrated in a controlled human study that the absolute intakes of LA and ALA – not merely their ratio – determine the conversion of ALA to EPA (Baker et al., 2016; Retterstøl & Rosqvist, 2024).

Fourth, the ratio can be calculated from diet, from blood, from different blood fractions, and from different tissues – and each yields a different number. There is no standardised way to measure or interpret an “optimal ratio”, and no health authority has issued a quantitative recommendation for a specific ω‑6:ω‑3 ratio (Jackson et al., 2024).

Consequently, the current consensus among many experts is that the ω‑6:ω‑3 ratio is not a useful guide for dietary recommendations. Instead, attention should focus on the absolute intake of each key fatty acid – LA, ALA, EPA and DHA – and on the quality of the foods that provide them (Jackson et al., 2024; Retterstøl & Rosqvist, 2024).

4.2 Adequate intakes: preventing deficiency versus promoting optimal function

The concept of “adequate intake” (AI) for essential fatty acids has evolved. The original goal was to identify the minimum amount needed to prevent classical signs of deficiency – dermatitis, poor growth, reproductive failure. For LA, this threshold is very low: approximately 1‑2% of total energy. For ALA, the minimum is similarly low, around 0.5% of energy (Plourde & Cunnane, 2007). Intakes at these levels reliably prevent overt EFA deficiency in healthy individuals.

However, preventing deficiency is not the same as supporting optimal health. Most national and international guidelines therefore recommend higher intakes. For example, the Nordic Nutrition Recommendations 2023 (NNR2023) propose the following ranges for adults (Retterstøl & Rosqvist, 2024; Jackson et al., 2024):

  • Total fat: 25‑40% of energy (E%).
  • Saturated fatty acids: less than 10 E%.
  • ω‑6 PUFA (primarily LA): 5‑10 E%.
  • ω‑3 PUFA: at least 1 E%, of which at least 0.5 E% should be ALA.
  • For pregnant and lactating women: ω‑3 PUFA should contribute at least 1 E%, including at least 200 mg/day of DHA.

The recommendation for ω‑6 PUFA (5‑10 E%) corresponds to approximately 11‑22 g/day of LA on a 2000 kcal diet. This range is consistent with current average intakes in many Western countries, suggesting that most people already consume LA within or above the recommended range. Indeed, NNR2023 notes that current LA intakes in Nordic and Baltic countries fall within the 5‑10 E% range associated with improved cardiometabolic health (Jackson et al., 2024).

For ALA, the recommendation of at least 0.5 E% is easily met by consuming modest amounts of flaxseed, walnuts, canola oil, or soybean oil. However, many individuals do not meet the recommended intake for EPA and DHA, which are not technically “essential” (since they can be synthesised from ALA, albeit inefficiently) but are nonetheless important for optimal function. The NNR2023 recommends that adults consume 300‑450 g of fish per week (ready‑to‑eat weight), of which at least 200 g should be fatty fish, to provide adequate EPA and DHA (Retterstøl & Rosqvist, 2024).

4.3 The precursor dilemma: can ALA replace EPA and DHA?

This question is central to dietary planning for vegetarians, vegans, and individuals who consume little or no seafood. The metabolic evidence, reviewed in Part 2, provides a clear answer: for EPA, partial replacement is possible; for DHA, it is not, at least in most adults.

EPA. Increasing ALA intake does raise blood levels of EPA in a dose‑dependent manner. A meta‑analysis of intervention studies found that each additional gram of ALA per day increases plasma phospholipid EPA by approximately 10% (Baker et al., 2016). However, the absolute increase is modest. To raise EPA levels to those achieved by moderate fish consumption (e.g., two servings of fatty fish per week, providing ~250 mg/day of EPA+DHA), one would need to consume very high amounts of ALA – possibly 5‑10 g/day or more – while simultaneously keeping LA intake low to minimise competition. This is achievable in principle but difficult in practice for most people.

DHA. The evidence is unambiguous: increasing ALA intake does not raise blood DHA levels in healthy adults, except perhaps in young women with high oestrogen levels. In most intervention studies, DHA either remains unchanged or decreases slightly when ALA is increased (Baker et al., 2016; Plourde & Cunnane, 2007). The decrease is thought to reflect a dilution effect: as ALA and EPA increase in membrane lipids, the proportion of DHA falls, even if its absolute amount remains constant. Importantly, no study has demonstrated a meaningful increase in tissue DHA from ALA alone in healthy adults consuming typical diets.

Thus, for individuals who do not consume fish or other marine sources, ALA cannot serve as an adequate substitute for DHA. This has led to the recognition that DHA is a “conditionally essential” nutrient – essential under certain conditions (e.g., infancy, pregnancy, possibly ageing) and for individuals with limited capacity to synthesise it from ALA. The European Food Safety Authority (EFSA) has therefore mandated the addition of DHA to infant formulas, and many experts recommend DHA supplements for pregnant and lactating women who do not eat fish (Jackson et al., 2024; Hashimoto et al., 2017).

4.4 New sources and bioavailability considerations

Traditional sources of long‑chain ω‑3 PUFAs are fatty fish and fish oils. However, concerns about overfishing, environmental contaminants, and sustainability have driven the search for alternative sources. Two promising alternatives are algal oils and krill oil.

Algal oils. Certain microalgae (e.g., Schizochytrium sp., Crypthecodinium cohnii) naturally produce high concentrations of DHA and, in some strains, EPA. Algal oil is the original source of DHA in the marine food chain – fish accumulate DHA by consuming algae. Algal oils are sustainable, free of the contaminants sometimes found in fish, and suitable for vegetarians and vegans. They provide DHA directly, bypassing the inefficient conversion from ALA (Djuricic & Calder, 2021).

Krill oil. Krill are small crustaceans that occupy a lower trophic level than fish. Krill oil contains EPA and DHA primarily in the form of phospholipids, whereas fish oil contains them mainly as triacylglycerols. Some studies suggest that phospholipid‑bound EPA and DHA may be better absorbed and more efficiently delivered to tissues, particularly the brain, although the evidence is not yet conclusive (Saini & Keum, 2018; Djuricic & Calder, 2021).

Plant sources with enhanced ALA or SDA. Traditional plant oils (flaxseed, canola, soybean) provide ALA. Genetically modified soybean oil enriched in stearidonic acid (SDA) – the immediate Δ6‑desaturase product of ALA – has been developed. Because SDA bypasses the rate‑limiting Δ6‑desaturation step, it is converted to EPA more efficiently than ALA. Human studies confirm that SDA supplementation raises EPA levels more effectively than ALA, but still does not increase DHA (Baker et al., 2016). SDA‑enriched oils are commercially available in some markets.

Beyond the type of fatty acid, the chemical form matters for bioavailability. Long‑chain PUFAs can be present as:

  • Triacylglycerols (TAGs): The natural form in fish oil and most plant oils. Requires pancreatic lipase digestion to free fatty acids and monoacylglycerols before absorption.
  • Ethyl esters (EEs): A synthetic form used in some concentrated supplements. Less efficiently absorbed than TAGs, especially when taken with low‑fat meals.
  • Phospholipids (PLs): The form in krill oil and in cell membranes. May be better absorbed because they are water‑dispersible and can be taken up directly by enterocytes after partial digestion by phospholipase A₂.
  • Free fatty acids (FFAs): The most readily absorbed form, but prone to oxidation and rarely used in commercial products.

For most people consuming typical doses (1‑2 g/day of EPA+DHA), the differences in bioavailability between TAGs and EEs are small and can be overcome by taking ethyl ester supplements with a fat‑containing meal. However, for high‑dose supplementation or for individuals with malabsorption, the form may become clinically relevant (Saini & Keum, 2018).

4.5 Current intake patterns and public health considerations

In the Nordic and Baltic countries, as in most developed nations, average intakes of total fat range from 34 to 44% of energy. Saturated fat intake is generally above the recommended limit of 10 E%, while ω‑6 PUFA intake (mostly LA) falls within the 5‑10 E% range. ω‑3 PUFA intake is highly variable: individuals who consume fatty fish regularly have adequate EPA+DHA intakes, while those who do not often fall below recommended levels (Retterstøl & Rosqvist, 2024; Jackson et al., 2024).

The ratio of LA to ALA in typical diets is approximately 6‑10:1, reflecting the abundance of LA in vegetable oils and processed foods and the relative scarcity of ALA. This ratio is far from the 1‑4:1 sometimes advocated by proponents of the “low ω‑6” hypothesis. However, as argued above, the ratio itself is not a reliable target; what matters is that LA intake is not excessive (above 10 E%) and that ALA, EPA and DHA intakes meet recommended levels.

Public health strategies to improve PUFA intake focus on:

  • Replacing saturated fats with unsaturated fats. This includes using vegetable oils (canola, olive, sunflower) instead of butter, lard, or tropical oils (palm, coconut).
  • Increasing fish consumption. Especially fatty fish (salmon, mackerel, herring, sardines), 2‑3 times per week.
  • Using ALA‑rich oils. Flaxseed oil, canola oil, and soybean oil as part of a varied diet.
  • Considering fortified foods or supplements. For individuals who do not eat fish, particularly pregnant and lactating women, the elderly, and strict vegetarians/vegans (Retterstøl & Rosqvist, 2024; Jackson et al., 2024).

4.6 Summary: moving beyond ratios

The modern understanding of essential fatty acid nutrition has moved away from simplistic ω‑6:ω‑3 ratios and towards a more nuanced appreciation of individual fatty acids. Key takeaways include:

  • LA is not inherently harmful. Current intakes (5‑10 E%) are consistent with recommendations and are associated with favourable cardiometabolic profiles. There is no evidence that reducing LA intake below current levels would provide additional benefits for the general population.
  • ALA is an essential nutrient, but a poor source of DHA. Increasing ALA intake raises EPA levels modestly but does not increase DHA in most adults. For DHA, direct dietary sources (fish, algae) are necessary.
  • The ω‑6:ω‑3 ratio is not informative. It conflates different fatty acids with different functions, ignores absolute intakes, and varies depending on what is measured. Health authorities have not set ratio targets.
  • Both families are necessary. The goal is not to eliminate ω‑6 fatty acids, but to ensure adequate intake of long‑chain ω‑3 PUFAs (EPA and DHA) while avoiding excessive intake of any single fat source.

In the final part, we will summarise the key principles of essential fatty acid biology and highlight remaining questions for future research.

Conclusion: Key takeaways for understanding

We have travelled a long path – from the chemical structure of two simple 18‑carbon fatty acids to the complex signalling networks controlled by their long‑chain metabolites. Along the way, we have encountered rate‑limiting enzymes, genetic polymorphisms, competitive inhibition, and a remarkable family of pro‑resolving mediators that actively terminate inflammation. What, then, are the essential principles that emerge from this journey? For the student of nutrition, several key takeaways warrant emphasis.

1. Only two fatty acids are truly essential

Despite the dozens of polyunsaturated fatty acids present in human tissues and the many more that appear in foods, only two cannot be synthesised by the human body: linoleic acid (LA, 18:2ω‑6) and α‑linolenic acid (ALA, 18:3ω‑3). All other PUFAs – including arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) – can theoretically be made from these two precursors. The essentiality of LA and ALA arises from the absence of Δ12 and Δ15 desaturases in animals, enzymes that plants use to insert the first double bonds at the ω‑6 and ω‑3 positions. Without dietary provision, deficiency signs appear: dermatitis, growth retardation, reproductive failure, and – in the case of ALA deficiency – neurological and visual disturbances (Plourde & Cunnane, 2007; Jackson et al., 2024).

2. Conversion of precursors to long‑chain PUFAs is limited in humans

The desaturation‑elongation pathway that converts LA to AA and ALA to EPA and DHA is fully intact in humans, but its capacity is severely constrained. Stable isotope studies consistently show that less than 5‑10% of ALA is converted to EPA, and conversion to DHA is typically below 1% – often undetectable in men. Most dietary ALA is instead rapidly β‑oxidised to acetyl‑CoA and used as fuel or for the synthesis of saturated and monounsaturated fatty acids (Baker et al., 2016; Plourde & Cunnane, 2007). This low efficiency has profound implications: for DHA especially, endogenous synthesis cannot meet physiological demands in most adults. Direct dietary sources of pre‑formed DHA are therefore necessary for optimal status.

3. AA, EPA and DHA have distinct, non‑interchangeable roles

The three major long‑chain PUFAs are not interchangeable:

  • Arachidonic acid (AA) is the dominant ω‑6 PUFA in membrane phospholipids. It serves as a reservoir for eicosanoids – both pro‑inflammatory (e.g., PGE₂, LTB₄) and pro‑resolving (e.g., lipoxin A₄). Its presence is essential for normal host defence and tissue repair (Innes & Calder, 2018).
  • Eicosapentaenoic acid (EPA) acts primarily as a metabolic modulator. It competes with AA for access to COX and LOX enzymes, shifting eicosanoid production towards less inflammatory series‑3 and series‑5 mediators. EPA is also the precursor for E‑series resolvins, which actively promote resolution of inflammation (Djuricic & Calder, 2021; Ishihara et al., 2019).
  • Docosahexaenoic acid (DHA) is a unique structural fatty acid. Its six cis double bonds create a highly bent, fluid conformation that is essential for the function of excitable membranes – the retina, synapses, and cardiac tissue. DHA is also the parent molecule for D‑series resolvins, protectins, and maresins, among the most potent pro‑resolving mediators known (Hashimoto et al., 2017; Ishihara et al., 2019).

4. The ω‑6:ω‑3 ratio is not a useful target

For decades, dietary advice emphasised lowering the ratio of ω‑6 to ω‑3 fatty acids. This concept, while intuitively appealing, suffers from several flaws. It treats all ω‑6 fatty acids as equivalent (LA and AA are not), all ω‑3 fatty acids as equivalent (ALA, EPA and DHA are not), ignores absolute intakes, and can be calculated in many different ways yielding different numbers. No health authority has issued a quantitative recommendation for a specific ω‑6:ω‑3 ratio, and the scientific consensus has moved away from ratio‑based guidance. Instead, attention should focus on absolute intakes of individual fatty acids – particularly LA (5‑10% of energy), ALA (at least 0.5% of energy), and EPA+DHA (at least 250‑500 mg/day from marine sources) – within the context of an overall healthy dietary pattern (Jackson et al., 2024; Retterstøl & Rosqvist, 2024).

5. Plant sources provide ALA, but not adequate DHA for most adults

Vegetarians and vegans can obtain ALA from flaxseed, walnuts, canola oil, and soy products. This ALA will partially convert to EPA (raising EPA levels modestly) but will not meaningfully increase DHA in most individuals. For those who do not consume fish or other marine products, DHA status may become suboptimal, with potential implications for brain health, visual function, and cardiovascular risk over the long term. Algal oils offer a sustainable, plant‑based source of pre‑formed DHA that bypasses the inefficient conversion pathway. For strict vegetarians and vegans, especially during pregnancy, lactation, and early childhood, direct DHA supplementation or consumption of DHA‑fortified foods is a prudent consideration (Baker et al., 2016; Hashimoto et al., 2017).

6. Modern understanding respects complexity

The science of essential fatty acids has matured from the era of “vitamin F” and simplistic EFA deficiency models to a sophisticated understanding of enzyme regulation, genetic variability, and lipid mediator networks. We now know that desaturase activity varies with sex (oestrogen increases conversion), age (infants convert better than adults), genetics (common FADS polymorphisms affect AA and DHA status), and nutritional status (micronutrient deficiencies impair the pathway). We have discovered that inflammation is not merely turned off but actively resolved by SPMs derived from EPA and DHA. And we have learned that the old dichotomy of “good ω‑3” versus “bad ω‑6” is an oversimplification that does not serve public health.

Remaining questions for future research

Despite decades of research, several important questions remain open:

  • Individual variability. Can we develop simple genetic or metabolic tests to predict who will benefit most from increased ALA intake and who requires pre‑formed DHA?
  • DHA requirements across the life course. Do the elderly have higher DHA requirements than younger adults? Is there a threshold below which cognitive decline accelerates?
  • Interactions with the gut microbiome. Do gut bacteria metabolise PUFAs into bioactive compounds? Can the microbiome influence host PUFA status?
  • Sex differences. Why do women convert ALA to DHA more efficiently than men? Does this confer differential disease risks or nutritional requirements?
  • Novel mediators. What are the functions of newly discovered lipid mediators such as MCTRs, PCTRs, and RCTRs? Do they have therapeutic potential?
  • Food matrix effects. How does the form of PUFAs (TAGs vs. PLs vs. FFAs) affect their absorption, tissue distribution, and biological actions in real‑world diets?

Final word

Essential fatty acids are not a fad, a supplement category, or a target for dietary fear‑mongering. They are fundamental components of human biology – as essential as any vitamin or mineral. Linoleic acid and α‑linolenic acid are indispensable because they provide the raw material for a family of long‑chain PUFAs that orchestrate membrane structure, cell signalling, inflammation, and its resolution. The pathway from plant‑derived precursors to these active molecules is, however, limited in humans. This limitation is not a design flaw; it is a reflection of our evolutionary history as a species that consumed marine foods rich in pre‑formed EPA and DHA. Recognising this metabolic reality allows us to make informed dietary choices: to value plant sources of ALA, to include marine sources of EPA and DHA when possible, and to appreciate the elegant complexity of the lipid signalling networks that keep our cells – and our bodies – in balance.

References

  1. Baker, E.J., Miles, E.A., Burdge, G.C., Yaqoob, P. and Calder, P.C. (2016) ‘Metabolism and functional effects of plant-derived omega-3 fatty acids in humans’, Progress in Lipid Research, 64, pp. 30-56. DOI: 10.1016/j.plipres.2016.07.002 PubMed
  2. Djuricic, I. and Calder, P.C. (2021) ‘Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021’, Nutrients, 13(7), 2421. DOI: 10.3390/nu13072421 PubMed
  3. Hashimoto, M., Hossain, S., Al Mamun, A., Matsuzaki, K. and Arai, H. (2017) ‘Docosahexaenoic acid: one molecule diverse functions’, Critical Reviews in Biotechnology, 37(5), pp. 579-597. DOI: 10.1080/07388551.2016.1207153 PubMed
  4. Innes, J.K. and Calder, P.C. (2018) ‘Omega-6 fatty acids and inflammation’, Prostaglandins, Leukotrienes and Essential Fatty Acids, 132, pp. 41-48. DOI: 10.1016/j.plefa.2018.03.004 PubMed
  5. Ishihara, T., Yoshida, M. and Arita, M. (2019) ‘Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis’, International Immunology, 31(9), pp. 559-567. DOI: 10.1093/intimm/dxz001 PubMed
  6. Jackson, K.H., Harris, W.S., Belury, M.A., Kris-Etherton, P.M. and Calder, P.C. (2024) ‘Beneficial effects of linoleic acid on cardiometabolic health: an update’, Lipids in Health and Disease, 23, 296. DOI: 10.1186/s12944-024-02246-2 PubMed
  7. Nordic Council of Ministers (2023) Nordic Nutrition Recommendations 2023: Integrating Environmental Aspects. Copenhagen: Nordic Council of Ministers. Nord 2023:003. DOI: 10.6027/nord2023-003
  8. Plourde, M. and Cunnane, S.C. (2007) ‘Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements’, Applied Physiology, Nutrition, and Metabolism, 32(4), pp. 619-634. DOI: 10.1139/H07-034 PubMed
  9. Retterstøl, K. and Rosqvist, F. (2024) ‘Fat and fatty acids - a scoping review for Nordic Nutrition Recommendations 2023’, Food & Nutrition Research, 68, 9980. DOI: 10.29219/fnr.v68.9980 PubMed
  10. Saini, R.K. and Keum, Y.-S. (2018) ‘Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review’, Life Sciences, 203, pp. 255-267. DOI: 10.1016/j.lfs.2018.04.049 PubMed